SCHEMBL753494

SCHEMBL753494

CCOC(=O)C(=O)O[C@@](CC)(c1cccc(OC)c1)[C@@H](C)CN(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.43
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
MRGPRX2 Q96LB1 1/20 0.43
CHRM3 P20309 1/20 0.43
HRH2 P25021 1/20 0.43
HTR2A P28223 1/20 0.43
ADRA1A P35348 1/20 0.43
OPRK1 P41145 1/20 0.43
CYP2D6 P10635 2/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALDH1A1 P00352 4/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MTNR1B P49286 2/20 0.38
MTNR1A P48039 1/20 0.38
HSD17B10 Q99714 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755809 0.87 KCNH2 (0.46) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL14516176 0.87 KCNH2 (0.46) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL22454446 0.81 CYP2D6 (0.40) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL17750791 0.81 CYP2D6 (0.40) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL14987836 0.81 KCNH2 (0.41) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL16751400 0.81 KCNH2 (0.45) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL669655 0.80 KCNH2 (0.38) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL14974361 0.80 KCNH2 (0.38) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL669373 0.80 KCNH2 (0.38) KCNH2OPRM1OPRD1MRGPRX2CHRM3
SCHEMBL14984858 0.80 KCNH2 (0.38) KCNH2OPRM1OPRD1MRGPRX2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160102047-A1 SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHOD AND THE USE THEREOF TOPHARMAN SHANGHAI CO., LTD. (CN) 2016-04-14 US disclosed
US-9249084-B2 Substituted n-pentanamide compounds, preparation method and the use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2016-02-02 US disclosed
US-20140046074-A1 Substituted n-pentanamide compounds, preparation method and the use thereof TOPHARMAN SHANGHAI CO., LTD. (CN) 2014-02-13 US disclosed
US-8440863-B2 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine JANSSEN PHARMACEUTICA, NV (BE) 2013-05-14 US disclosed
US-8440863-B2 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine JANSSEN PHARMACEUTICA, NV (BE) 2013-05-14 US disclosed
US-20120142970-A1 PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2 TRIMETHYLPENTANAMINE FILLIERS WALTER FERDINAND MARIA (BE) 2012-06-07 US disclosed
US-20120142970-A1 PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2 TRIMETHYLPENTANAMINE FILLIERS WALTER FERDINAND MARIA (BE) 2012-06-07 US disclosed
US-8138376-B2 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine JANSSEN PHARMACEUTICA, NV (BE) 2012-03-20 US disclosed
US-8138376-B2 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine JANSSEN PHARMACEUTICA, NV (BE) 2012-03-20 US disclosed
US-20090312578-A1 PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENTANAMINE JANSSEN PHARMACEUTICA NA (BE) 2009-12-17 US disclosed
US-20090312578-A1 PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENTANAMINE JANSSEN PHARMACEUTICA NA (BE) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102047-A1 SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHOD AND THE USE THEREOF PNMT, TPMT, HTR3A KCNH2 549/4885OPRM1 32/4885OPRD1 56/4885
US-20120142970-A1 PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2 TRIMETHYLPENTANAMINE PNMT, HTR3C, OPRL1 KCNH2 607/4885OPRM1 8/4885OPRD1 6/4885
US-20090312578-A1 PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENTANAMINE PNMT, HTR3A, HTR3C KCNH2 617/4885OPRM1 8/4885OPRD1 6/4885
US-20140046074-A1 Substituted n-pentanamide compounds, preparation method and the use thereof PNMT, TPMT, HTR3A KCNH2 552/4885OPRM1 41/4885OPRD1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.